A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Description

This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.

Conditions

Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Santa Monica

Sarcoma Oncology Center, Santa Monica, California, United States, 90403

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Histological confirmed recurrent metastatic breast cancer which has failed prior
  • 1. Human epidermal growth factor 2 (EGFR2, HER2) positive tumors must have failed therapy with at least 2 anti-HER2 agents
  • 2. HER2 negative and either ER or PR positive tumors: must be refractory to hormonal therapy and previously treated with at least 2 hormone based targeted therapy containing regimens.
  • 3. Triple-negative and inflammatory tumors must have exhausted other curative intent therapies including prior treatment with a taxane and platinum-based agent
  • 4. All other MBC types must have exhausted other curative intent therapies including any genomic or germline directed targeted therapy having available approved drug(s)
  • 5. Patients with new or progressive breast cancer metastatic to the brain will be eligible, provided:
  • 2. Be 18 years of age or older.
  • 3. Have expected survival of at least 4 months.
  • 4. Have adequate performance status (up to and including ECOG 2)
  • 5. Patients must be stable with all known or expected toxicities from previous treatment including:
  • 1. Prior immune related toxicity must not have exceeded Grade 2 with exception of stable endocrinopathy (endocrinopathy if well-managed, is not exclusionary).
  • 2. Toxicity of prior therapy that has not recovered to ≤ grade 1 or baseline (with the exception of any grade of alopecia, adequately treated endocrinopathy, and anemia not requiring transfusion support).
  • 1. Concurrent anti-cancer treatment.
  • 2. Recent chemotherapy, radiotherapy, or other anti-cancer treatment within 3 weeks of first protocol treatment.
  • 3. Participant has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.
  • 4. History of clinical hypersensitivity to the designated therapy, as specified in the protocol or to any components used in the preparation of any cell line in this study.
  • 5. History of clinical hypersensitivity to any protocol specified therapy.
  • 6. BUN \>30 in conjunction with a creatinine \>2, or calculated creatinine clearance (CrCl) \<30 mL/min (GFR can be used in place of creatinine or CrCl).
  • 7. Absolute granulocyte count \< 1000; platelets \<50,000.
  • 8. Bilirubin \>2.0; alkaline phosphatase \>4x upper limit of normal (ULN); ALT/AST \>2x ULN. For patients with hepatic metastases, ALT/AST \>5x ULN is exclusionary.
  • 9. Proteinuria \>1+ on urinalysis or \>1 gm/24hr.
  • 10. New York Heart Association stage 3 or 4 cardiac disease.
  • 11. A pleural or pericardial effusion of moderate severity or worse.
  • 12. Any woman of childbearing potential (i.e., has had a menstrual cycle within the past year and has not been surgically sterilized), unless she: agrees to take appropriate precautions to avoid becoming pregnant during the study and has a negative serum pregnancy test within 7 days prior to starting treatment.
  • 13. Men who are fertile/reproductively competent, should take appropriate precautions to avoid fathering a child for the duration of the study.
  • 14. Women who are pregnant or nursing.
  • 15. Patients with concurrent second malignancy.
  • 16. Persons with previous malignancies requiring treatment within the past 24 months.
  • 17. Patients who have clinical or laboratory features indicative of AIDS and are HIV positive (by self-report).
  • 18. Have a diagnosis of immunodeficiency, or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent), or any other form of immunosuppressive therapy within 21 days prior to first dose of study treatment.
  • 19. Patients who are on treatment for an autoimmune disease, unless specifically approved by the Investigator and the Sponsor.
  • 20. Patients with severe psychiatric (e.g., schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator and Sponsor.
  • 21. Patients may not be on a concurrent clinical trial, unless approved by Investigator and Sponsor.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

BriaCell Therapeutics Corporation,

Giuseppe Del Priore, MD, MPH, STUDY_CHAIR, BriaCell Therapeutics Corp

Victoria Chua-Alcala, MD, STUDY_DIRECTOR, Sarcoma Oncology Research Center

Study Record Dates

2025-10-30